SG Americas Securities LLC Sells 2,213 Shares of IVERIC bio, Inc. (NASDAQ:ISEE)

SG Americas Securities LLC lessened its stake in shares of IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) by 6.2% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,630 shares of the company’s stock after selling 2,213 shares during the quarter. SG Americas Securities LLC’s holdings in IVERIC bio were worth $566,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its holdings in IVERIC bio by 36.9% in the 1st quarter. Nisa Investment Advisors LLC now owns 3,230 shares of the company’s stock valued at $54,000 after acquiring an additional 870 shares in the last quarter. DekaBank Deutsche Girozentrale raised its holdings in IVERIC bio by 169.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 77,700 shares of the company’s stock valued at $1,268,000 after acquiring an additional 48,900 shares in the last quarter. Alta Wealth Advisors LLC raised its holdings in IVERIC bio by 140.2% in the 1st quarter. Alta Wealth Advisors LLC now owns 34,265 shares of the company’s stock valued at $577,000 after acquiring an additional 20,000 shares in the last quarter. Aevitas Wealth Management Inc. acquired a new position in IVERIC bio in the 1st quarter valued at approximately $361,000. Finally, Belvedere Trading LLC acquired a new position in IVERIC bio in the 1st quarter valued at approximately $283,000.

IVERIC bio Stock Performance

Shares of ISEE opened at $11.45 on Thursday. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -9.39 and a beta of 1.51. The business’s fifty day moving average price is $10.58 and its two-hundred day moving average price is $13.20. IVERIC bio, Inc. has a 52 week low of $8.37 and a 52 week high of $19.34.

IVERIC bio (NASDAQ:ISEEGet Rating) last announced its quarterly earnings data on Tuesday, July 26th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). During the same quarter in the previous year, the company posted ($0.32) earnings per share. As a group, research analysts forecast that IVERIC bio, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Stifel Nicolaus upped their price target on IVERIC bio from $22.00 to $28.00 in a report on Wednesday, May 4th. UBS Group began coverage on IVERIC bio in a report on Tuesday. They issued a “buy” rating and a $20.00 target price for the company. B. Riley began coverage on IVERIC bio in a report on Thursday, May 12th. They issued a “neutral” rating and a $12.00 target price for the company. Credit Suisse Group increased their target price on IVERIC bio to $24.00 in a report on Friday, May 20th. Finally, Guggenheim began coverage on IVERIC bio in a report on Wednesday, June 8th. They issued a “buy” rating and a $30.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.20.

Insider Buying and Selling at IVERIC bio

In related news, Director Calvin W. Roberts purchased 25,000 shares of IVERIC bio stock in a transaction dated Monday, June 13th. The shares were acquired at an average cost of $9.62 per share, for a total transaction of $240,500.00. Following the transaction, the director now directly owns 32,500 shares of the company’s stock, valued at $312,650. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other IVERIC bio news, EVP Anthony S. Gibney sold 7,791 shares of IVERIC bio stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $9.41, for a total transaction of $73,313.31. Following the transaction, the executive vice president now directly owns 10,959 shares in the company, valued at $103,124.19. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Calvin W. Roberts bought 25,000 shares of IVERIC bio stock in a transaction on Monday, June 13th. The shares were acquired at an average price of $9.62 per share, for a total transaction of $240,500.00. Following the completion of the acquisition, the director now owns 32,500 shares of the company’s stock, valued at approximately $312,650. The disclosure for this purchase can be found here. Corporate insiders own 2.70% of the company’s stock.

About IVERIC bio

(Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Featured Stories

Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio, Inc. (NASDAQ:ISEEGet Rating).

Institutional Ownership by Quarter for IVERIC bio (NASDAQ:ISEE)

Want More Great Investing Ideas?

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.